Global monoclonal antibodies market to flourish by 2013
The study indicates that the usage of monoclonal antibody for the treatment of cancer has recorded explosive growth in recent years.
In fact, oncology was the most dominant therapeutic area for marketed monoclonal antibodies with around 42 percent of the total monoclonal antibody revenue coming from the sales of antibodies for cancer treatment in 2009, said research firm RNCOS.
The report reveals that rising incidences of cancer coupled with growing health insurance industry will drive renewed interests of the investors in the monoclonal antibodies therapeutics market for oncology at the global level.
Further, introduction of new products will lead to intense competition from already established brands in the coming years, which will further drive the market segment. Besides, the research report provides a thorough research and prudent analysis of Global protein therapeutics market.
The systematic and thorough research, studies the global protein therapeutics market to give an insight into its various segments, including monoclonal antibodies, erythropoietins, insulin, interferon, human growth hormone, blood clotting factor, granulocyte colony stimulating factor, and follicle stimulating hormone.
The analysis of the market states monoclonal antibodies as the current highest share-holder but future will see insulin segment posting a rapid growth, added the research firm.
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.